Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1222089 | 0.71 | THRB (0.30) | — | |
| SCHEMBL5822729 | 0.68 | KDM4E (0.39) | SLC6A7KDM4ECYP2C19ALDH1A1TSHR | |
| SCHEMBL20358219 | 0.64 | RXRA (0.31) | — | |
| SCHEMBL5822737 | 0.60 | SLC6A7 (0.42) | SLC6A7 | |
| SCHEMBL3577960 | 0.60 | SLC6A7 (0.41) | SLC6A7KDM4ECYP2C19 | |
| SCHEMBL3582563 | 0.60 | SLC6A7 (0.52) | SLC6A7KDM4EALDH1A1 | |
| SCHEMBL28788963 | 0.60 | — | — | |
| SCHEMBL1024219 | 0.60 | KDM4E (0.41) | SLC6A7KDM4ECYP2C19 | |
| SCHEMBL3572446 | 0.59 | SLC6A7 (0.70) | SLC6A7 | |
| SCHEMBL27587155 | 0.58 | RAB9A (0.33) | CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772291-B2 | Multicyclic compounds and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20100081691-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081691-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF THEIR USE | GRIN2C, CHAT, COMT | SLC6A7 1113/4885KDM4E 3142/4885AGTR2 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.